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Abstract. The present study investigated the effects of the 
combined treatment of two peptide nucleic acids (PNAs), 
directed against microRNAs involved in caspase-3 mRNA 
regulation (miR-155-5p and miR-221-3p) in the temozolomide 
(TMZ)-resistant T98G glioma cell line. These PNAs were 
conjugated with an octaarginine tail in order to obtain an 
efficient delivery to treated cells. The effects of singularly 
administered PNAs or a combined treatment with both PNAs 
were examined on apoptosis, with the aim to determine whether 
reversion of the drug-resistance phenotype was obtained. 
Specificity of the PNA-mediated effects was analyzed by 
reverse transcription-quantitative polymerase-chain reaction, 
which demonstrated that the effects of R8-PNA-a155 and 
R8-PNA-a221 anti-miR PNAs were specific. Furthermore, the 
results obtained confirmed that both PNAs induced apoptosis 
when used on the temozolomide-resistant T98G glioma 
cell line. Notably, co-administration of both anti-miR-155 
and anti-miR-221 PNAs was associated with an increased 
proapoptotic activity. In addition, TMZ further increased 
the induction of apoptosis in T98G cells co-treated with 
anti-miR-155 and anti-miR-221 PNAs.
Introduction
Glioblastoma multiforme (GBM) is a lethal malignant tumor 
accounting for 42% of the tumors of the central nervous 
system, with a median survival of 15 months (1-3). At present, 
no curative treatment is available and the most used first-line 
drug, temozolomide (TMZ), only moderately increases the 
life expectancy of the treated patients (4). In addition, a high 
proportion of gliomas become TMZ-resistant with time. 
Therefore, novel drugs and therapeutic protocols for combined 
treatments on TMZ-resistant glioma cells are urgently needed.
In this respect, a novel strategy for therapeutic protocols 
has been recently suggested, the targeting of microRNAs. 
MicroRNAs (miRNAs) are short non-coding RNAs that 
function by repressing translation or inducing the cleavage 
of the target mRNA transcripts, thereby regulating gene 
expression at the post-transcriptional level (5-7). Altered 
miRNA expression has been firmly demonstrated to be 
involved in cancer (8-13). Approaches based on the targeting 
of oncomiRNAs and metastamiRNAs (associated with 
tumor progression and metastasis, respectively) have been 
found to inhibit tumor cell growth and metastasis, and in 
some examples to reverse the resistance of tumor cells to 
anticancer drugs (14-17). For instance, Chan et al (15) have 
reported that the inhibition of oncomiR-138 prevents in vitro 
tumor sphere formation in malignant gliomas and suppresses 
in vivo tumorigenesis. Wagenaar et al (16) were able to target 
the transcriptional network in hepatocellular carcinomas cell 
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lines with sequence-specific antagomiR targeting miR-21, 
thereby inducing increased expression of miR-21-regulated 
genes, associated with a loss of viability. In another example, 
Ma et al (17) reported inhibition of metastasis formation in a 
mouse model of mammary tumor following silencing of the 
oncogenic miR-10a. In this context, the use of peptide nucleic 
acids (PNAs) targeting oncomiRNAs might be relevant (8).
PNAs are DNA analogues described for the first time by 
Nielsen et al (18), in which the sugar-phosphate backbone has 
been replaced by N-(2-aminoethyl)glycine units (18-22). PNAs 
are capable of forming Watson-Crick double helices following 
efficient sequence-specific hybridization with complementary 
DNA and RNA (23). Furthermore, they are able to generate 
triple helices with double-stranded DNA and to perform 
strand invasion (24-26). In virtue of these biological activities, 
PNAs have been demonstrated to be very efficient tools for 
pharmacologically-mediated alteration of gene expression, 
both in vitro and in vivo (27-29). In summary, PNAs and 
PNA-based analogues were employed as antisense molecules 
targeting mRNAs, triple-helix forming molecules targeting 
eukaryotic gene promoters, artificial promoters, and decoy 
molecules targeting transcription factors (26). Relevant to the 
present study, PNAs have been demonstrated to be able of 
altering miRNA functions, both in vitro and in vivo (30-37). 
Cheng et al (37), for instance, efficiently inhibited the 
function of oncomiR-155-5p in a tumor mouse model by the 
design and synthesis of a peptide-(anti-miR)-PNA construct 
able to target the tumor microenvironment and to transport 
the anti-miR PNA across the cellular plasma membranes 
under the acidic conditions which characterize solid tumors. 
Recently, our group has reported that a PNA targeting 
miR-221-3p (R8-PNA-a221) (38), bearing an oligoarginine 
peptide (R8) enabling efficient uptake by glioma cells (30,31), 
was able to strongly inhibit miR-221-3p in U251, U373 and 
T98G glioma cells. The inhibition of miR-221-3p activity was 
associated with an increased expression of the miR-221-3p 
target p27Kip1, as analyzed by reverse transcription-quantitative 
polymerase-chain reaction (RT-qPCR) and by western blot 
analysis (38).
The present study determined the biological activity of a 
combined treatment of glioma cell lines with two PNAs directed 
against miRNAs regulating caspase-3 mRNA expression and 
conjugated to the octaarginine R8 peptide, allowing efficient 
cellular uptake. Effects on apoptosis were analyzed to determine 
whether additive activity was were obtained by co-administration 
of the two PNAs to the temozolomide-resistant T98G glioma 
cell line, and whether combined treatments were associated 
with a reversion of the drug-resistance phenotype.
Materials and methods
Synthesis and characterization of PNAs. The protocols for 
the synthesis and the characterization of the anti-miR-221 
PNAs have been described in a previously published 
study (38). The synthesis of the new anti-miR-155 PNAs was 
performed using a standard Fmoc-based automate peptide 
synthesizer (Syro I; Biotage, Uppsala, Sweden), using a 
ChemMatrix-RinkAmide resin loaded with Fmoc-Gly-OH 
(0.2 mmol/g) as first monomer, and using commercially 
available monomers (Link Technologies, Bellshill, UK) with 
HBTU/DIPEA coupling. After purification, the PNAs were 
characterized by UPLC-MS on a Waters ACQUITY System 
equipped with a ACQUITY UPLC BEH C18 Column(1.7 µm; 
2.1x50 mm). Gradient: 100% A for 0.9 min, then 0-50% B 
in 5.7 min at 0.25 ml/min flow (A, water + 0.2% formic 
acid; B, acetonitrile + 0.2% formic acid). R8-PNA-a155: 
sequence H-R8-TAT CAC GAT TAG CAT TAA-Gly-NH2; 
yield: 15.9% Rt=2.65 min; calculated MW, 6184.3 g/mol; m/z 
found, 1238.2 [M+5H]5+, 1031.9 [M+6H]6+, 884.8 [M+7H]7+, 
774.3 [M+8H]8+, 688.4 [M+9H]9+, 619.6 [M+10H]10+, 563.4 
[M+11H]11+. R8-PNA-a155-MUT: sequence H-R8-TAT TAC 
GGT TAA CAT CAA-Gly-NH2; yield: 11.6% Rt=2.65 min; 
calculated mw, 6184.3 g/mol; m/z found, 1238.0 [M+5H]5+, 
1032.0 [M+6H]6+, 884.7 [M+7H]7+, 774.2 [M+8H]8+, 688.4 
[M+9H]9+, 619.6 [M+10H]10+, 563.3 [M+11H]11+.
Glioma cell lines and culture conditions. T98G cells (39-41) 
were grown in RPMI-1640 medium (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA) supplemented with 10% fetal 
bovine serum (FBS; EUROCLONE S.p.A., Pero, Italy), 100 U/
ml penicillin and 100 mg/ml streptomycin, in humidified 
atmosphere of 5% CO2/air. In order to study possible 
anti-proliferative effects, the cell number/ml was monitored 
using a Z2 Coulter Counter (Coulter Electronics, Hialeah, FL, 
USA). Mycoplasma testing on T98G cells was performed prior 
to each experiment.
RNA extraction. Cultured cells were trypsinized and collected 
by centrifugation at 250 x g for 10 min at 4˚C. Then, cells 
were lysed with TRI Reagent (Sigma Aldrich; Merck KGaA, 
Darmstadt, Germany) and the isolated RNA was washed once 
with cold 75% ethanol, dried and dissolved in nuclease-free 
pure water prior to use (36).
Quantitative analyses of miRNAs. For miRNA quantification 
using RT-qPCR, reagents, pr imers and probes for 
hsa-miR-221-3p and hsa-miR-155-5p were obtained from 
Applied Biosystems (Thermo Fisher Scientific, Inc.). Reverse 
transcription was performed using the TaqMan MicroRNA 
Reverse Transcription kit, with 20 ng per sample used for the 
assays. qPCR was performed as described elsewhere (36), 
using the CFX96 Touch Real-Time PCR Detection System 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). The relative 
miRNA content was calculated using the comparative cycle 
threshold method and U6 snRNA and has-let-7c were used 
as references to normalize all RNA samples, as previously 
described (38).
Analysis of caspase‑3 gene expression. Gene expression 
analysis was performed by RT-qPCR. Total RNA (500 ng) was 
reverse transcribed by using random hexamers. qPCR assays 
were performed using gene-specific double-fluorescently 
labeled probes. Primers and probes used to assay caspase-3 
gene expression were purchased from Applied Biosystems 
(Themo Fisher Scientific, Inc.). The relative expression was 
calculated using the comparative cycle threshold method and 
the human RPL13A (Assay ID: Hs04194366_g1) was used as 
a reference gene (30,31,38).
Caspase-3 protein activity was analyzed using Bio-PlexPro 
RBM Apoptosis Assays (Bio-Rad Laboratories, Inc.), an 
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immunoassay performed on magnetic beads. Glioblastoma 
cells were seeded in 6-well plates, treated with the compounds 
and after 72 h total cell extracts were prepared. Cells were 
washed with cold sterile PBS, centrifuged, the pellet was 
suspended in LDB (lysate dilution buffer) and after 8 thermal 
shock cycles using dry ice, the suspension was centrifuged at 4˚C 
for 10 min at 9000 x g. The supernatant was carefully removed 
and transferred into new vials, according to the manufacturer's 
instructions. Protein quantification was performed using 
BCA protein assay (Thermo Fisher Scientific, Inc.). For the 
analysis with Bio-PlexPro RBM Apoptosis Panel 3, samples 
were diluted to a final concentration of 500 µg/ml with 
LDB. After the reconstitution of the standard, seven serial 
1:3 dilutions were prepared and the assay was performed, 
according with the manufacturer's instructions. Briefly, after 
reaction with 10 µl of Blocking buffer, 10 µl of capture beads 
were added, the reaction incubated, washed three times with 
1X Assay buffer using Bio-Plex Pro Wash Station (Bio-Rad 
Laboratories, Inc.) and, finally, detection antibodies (40 µl) 
were added for a second incubation. Afterwards, 20 µl of diluted 
streptavidin-phycoerythrin (SA-PE) were added for 30 min at 
room temperature. After washing, the beads were suspended 
in 100 µl 1X Assay buffer, incubated with shaking for 30 sec 
and reading was performed at low PMT (photomultiplier tube) 
with Bio-Plex 200 Array reader (Bio-Rad Laboratories, Inc.). 
Data were analyzed with Bio-Plex Manager software (Bio-Rad 
Laboratories, Inc.).
Analysis of apoptosis. Annexin V and Dead Cell assay 
were performed on T98G cells using a Muse Cell Analyzer 
(Millipore Corporation, Billerica, MA, USA), as described 
elsewhere (38). Cells were washed with sterile PBS, 
trypsinized, suspended and diluted (1:2) with the one-step 
addition of the Muse Annexin V and Dead Cell reagent. After 
incubation for 20 min at room temperature in the dark, samples 
were analyzed. Data from prepared samples were acquired 
and recorded utilizing the Annexin V and Dead Cell Software 
Module (Millipore Corporation) (38).
Statistical analysis. Results are expressed as mean ± standard 
deviation. GraphPad Prism software version 5 (GraphPad 
Software, Inc., La Jolla, CA, USA) was used for statistical 
analysis. Comparison between groups was made by two-way 
analysis of variance with post-hoc Bonferroni comparison. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Identification of miRNA targets. First, it was confirmed that 
T98G are resistant to TMZ treatment, by determining the 
cell proliferation rate and the levels of induced apoptosis. 
As illustrated in Fig. 1A, the T98G cell line was resistant to 
TMZ treatment, with only a slight inhibition of cell growth 
observed when TMZ was used at very high concentrations 
(400 and 600 µM). By contrast, an IC50 inhibition was reached 
at 50 µM, when TMZ-sensitive U251 glioma cells were treated 
with TMZ (Fig. 1A). Furthermore, TMZ failed to induce a 
major increase in the proportion of Annexin V-positive cells 
when used in T98G cells (Fig.1B).
In order to identify possible miRNA targets for the present 
study, three sets of miRNAs were compared: miRNAs highly 
expressed in tissues from glioma patients; miRNAs validated 
in gliomas for their oncogenic properties; and miRNAs 
putatively interacting with the 3' untranslated region (UTR) of 
caspase-3 mRNA, which is deeply involved in activation of the 
apoptotic pathway. These lists of miRNAs are presented in the 
Tables SI-III. A Venn diagram for the comparison of the three 
lists is illustrated in Fig. 2A. Only three miRNA sequences 
were found in common within the three sets, miR-155-5p, 
miR-221-3p and miR-30a. Of note, miR-221-3p has already 
been demonstrated to exhibit anti-apoptotic effects in gliomas, 
and miR-221-3p targeting induces apoptosis and reverses 
TMZ-resistance (42). Similar information is available on the 
role of miR-155-5p, which regulates in the sensitization of 
glioma cell lines to antitumor drugs (43). By contrast, no report 
is available to date on the possible involvement of miR-30a to 
activation of drug resistance in gliomas. For these reasons, the 
present study focused on targeting miR-155-5p and miR-221-3p.
The location of the sites for these two miRNAs within the 
3'UTR sequences of the caspase-3 mRNA is shown in Fig. 2B, 
also depicting the extent of interactions between these two 
microRNAs and the caspase-3 mRNA sequences. When this 
Figure 1. (A) Effects of increasing concentrations (50-600 µM) of TMZ on 
the viability of U251 and T98G cells. Cells were cultured for 72 h with the 
indicated treatments and then the number of cells/ml was counted. (B) Lack 
of proapoptotic effects of TMZ in resistant T98G cells. T98G cells were 
cultured for 48 h without (white boxes) or with (black boxes) 400 µM TMZ and 
then the apoptosis rate was determined by flow cytometry. A representative 
plot is shown in the insert. Results are presented as the average ± standard 
deviation from four independent experiments.
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feature was compared with other miR-155-5p and miR-221-3p 
validated targets, it was observed that the level of interac-
tions is similar and compatible with a true caspase-3 mRNA 
regulation by miR-155-5p and miR-221-3p (data not shown). 
This is further sustained by the finding that miR-155-5p and 
miR-221-3p binding sites are of caspase-3 mRNA conserved 
through molecular evolution (Fig. 2C).
R8‑PNA‑a155 and R8‑PNA‑a221 exhibit inhibitory effects 
on miR‑155‑5p and miR‑221‑3p in glioma cells. Firstly, 
glioma cells were treated with increasing amounts of PNAs 
R8-PNA-a155 and R8-PNA-a221, targeting miR-155-5p and 
miR-221-3p, respectively. The results of the experiments are 
presented in Fig. 3A and B, and clearly demonstrate that 4 µM 
PNAs was the optimal concentration to significantly and 
reproducibly inhibit miR-155-5p (Fig. 3A) and miR-221-3p 
(Fig. 3B) hybridization signals.
Next, we determined whether the PNA-mediated effects 
were sequence-specific and selective for a given miRNA 
molecule. To test this, glioma cells were treated with 
Figure 2. (A) Identification of microRNAs highly expressed in gliomas, published as oncomiRNAs and potentially recognizing the 3'UTR of the caspase-3 
mRNA. The complete gene lists are included in Tables SI-III. (B) Location of the binding sites for miR-221-3p and miR-155-5p and extent of hybridization 
with the 3'UTR of the caspase-3 mRNA (accession no. NM_004346.3; Human caspase-3 Isoform 1). (C) Conservation throughout evolution of the caspase 3 
mRNA sequences corresponding to the miR-155-5p and miR-221-3p seed regions (bold font) of the caspase-3 mRNA throughout evolution. Human, mouse, rat 
and dog caspase-3 mRNA sequences are shown. The binding sites of miR-155-5p and miR-221-3p are boxed. UTR, untranslated region.
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R8-anti-miR155 PNA and R8-anti-miR221 PNA, and with 
PNAs including a mutated sequence R8-PNA-a155-MUT 
and R8-PNA-a221-MUT (Fig. 3C and D). Treatment of T98G 
cells with R8-PNA-a155 and R8-PNA-a221 resulted in a sharp 
and significant inhibition of miR-155-5p and miR-221-3p 
hybridization signals, respectively; by contrast, the mutant 
R8-anti-miR155-MUT PNA and R8-anti-miR221-MUT PNA 
displayed only minor effects (Fig. 3C and D). In a second set 
of experiments, results supporting the concept that the effects 
were specific were obtained. The results demonstrated that 
the miR-155-5p hybridization signal was strongly reduced 
only when RNA was isolated from glioma cells cultured 
for 48 h in the presence of R8-PNA-a155, with no major 
effects on miR-221-3p levels (Fig. 3E and F). Conversely, the 
miR-221-3p hybridization signal was significantly reduced 
only when RNA was isolated from glioma cells cultured for 
48 h in the presence of R8-PNA-a221, while no major effects 
on miR-221-3p levels were observed with R8-PNA-a155 
(Fig. 3E and F). Altogether these experiments support the 
concept that the effects of R8-PNA-155 on miR-155-5p, and 
of R8-PNA-a221 on miR-221-3p, are sequence-specific. As 
expected, miR-155-5p and miR-221-3p hybridization signals 
were reduced by co-administrating of R8-PNA-155 and 
R8-PNA-a221 (Fig. 3E and F).
Effects of R8‑PNA‑a155 and R8‑PNA‑a221 treatment on 
caspase‑3 expression. Since caspase-3 mRNA is a putative 
molecular target of miR-155-5p and miR-221-3p (Fig. 2B), 
the glioma T98G cell line was treated with R8-PNA-a155 
or R8-PNA-a221 and caspase-3 mRNA and protein levels 
were determined. To this aim, RNA was extracted for 
RT-qPCR analysis from an aliquot of cells, while another 
aliquot was used for preparing protein extracts for Bio-Plex 
analysis. The results demonstrated that treatment with 
R8-PNA-a155 or R8-PNA-a221 did not affect caspase-3 
mRNA levels (Fig. 4A). By contrast, both treatments resulted 
in a significant concentration-dependent increase of caspase-3 
protein production, as determined by Bio-Plex analysis 
(Fig. 4B). These results are compatible with a regulation of 
caspase-3 expression by miR-155-5p and miR-221-3p at the 
post-transcriptional level. Furthermore, analysis of caspase 3/7 
function confirmed the activation of the caspase-3/7 pathway 
in T98G cells treated with PNAs targeting miR-155-5p and 
miR-221-3p (Fig. 4C and D).
Effects of R8‑PNA‑a155 and R8‑PNA‑a221 treatment on 
apoptosis. The proapoptotic effects of R8-PNA-a155 and 
R8-PNA-a221 were confirmed to appear in a dose-dependent 
manner (Fig. 5A-D). Cells were cultured for 48 h in the 
Figure 3. Effects of PNAs targeting miR-155-5p and miR-221-3p on miRNA expression in T98G glioma cells. (A and B) Effects of 48 h treatment with 
increasing amounts of R8-PNA-a155 and R8-PNA-a221, as indicated. *P<0.05 and **P<0.01 vs untreated. (C and D) Effects of 48 h treatment with 4 µM 
R8-PNA-a155, R8-PNA-a221, R8-PNA-a155-MUT, R8-PNA-a221-MUT. **P<0.01 vs untreated. (E and F) Effects of 48 h treatment with the combination of 
R8-PNA-a155 and R8-PNA-a221, as indicated. **P<0.01 vs R8-PNA-a221 or R8-PNA-a155. Data are normalized to the miR-155-5p and miR-221-3p levels in 
untreated cells. Results are presented as the average ± standard deviation from three independent experiments. PNAs, peptide nucleic acids; MUT, mutated.
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absence (Fig. 5A) or in the presence of 0.5, 1, 2 and 4 µM 
R8-PNA-a155 (Fig. 5B) or R8-PNA-a221 (Fig. 5C) PNAs and 
the Annexin-V assay was performed. As clearly evident in 
Fig. 5D (which is in agreement with data in Fig. 3), only minor 
effects were observed when 0.5-2 µM PNAs were employed, 
and the higher proapoptotic effects were observed with 4 µM 
concentrations. When the glioma cell line T98G was cultured 
in the presence of singularly administered R8-PNA-a155 
or R8-PNA-a221 (used at 4 µM concentration) a significant 
increase of early and late apoptotic cells was found. Fig. 5E-G 
presents representative results obtained after treatment 
of T98G glioma cell lines with 4 µM R8-PNA-a155, and 
4 µM R8-PNA-a221, confirming the proapoptotic effects of 
R8-PNA-a221 (as previously published by our group) (38), 
and demonstrating for the first time the pro-apoptotic effects 
of R8-PNA-a155. Notably, when TMZ was also administered 
in combination with R8-PNA-a155 or R8-PNA-a221, a 
further significant increase of the proportion of apoptotic 
Annexin V-positive cells was observed (Fig. 5F-H). These 
data suggest that treatment of the TMZ-resistant T98G glioma 
cells with PNAs targeting miR-155-5p or miR-221-3p resulted 
in a sensitization of glioma cells to TMZ.
Effects of co‑treatment with suboptimal concentrations of 
R8‑PNA‑a155 or R8‑PNA‑a221 and TMZ on apoptosis. Since 
dose-dependent off-target effects of antisense molecules 
(including PNAs) is one of the major issues in this potential 
therapeutic strategy, the effects of combined treatments 
in the presence of 2 µM R8-PNA-a155 and R8-PNA-a221, 
which is half of the dose used in the experiments depicted 
in Fig. 5, were determined. As illustrated in Fig. 6, the levels 
of apoptosis induction reached by the co-administration of 
2 µM R8-PNA-a155 and 2 µM R8-PNA-a221 in T98G cells 
are similar to those obtained by singular administration of 
4 µM R8-PNA-a155 or R8-PNA-a221. This indicates that 
the use of suboptimal concentrations of anti-miR-155 and 
anti-miR-221 PNAs allows reaching high levels of apoptosis 
(Fig. 6A). This level was further increased when TMZ was 
added (Fig. 6A and B). These results demonstrated that 
co-administration of R8-PNA-a155 and R8-PNA-a221 induced 
apoptosis in TMZ-treated T98G cells at levels similar to those 
obtained following singular administration of high doses of 
R8-PNA-a155 or R8-PNA-a221.
Discussion
Because of the poor prognosis of gliomas and of the 
development of resistance to drugs commonly used in 
post-surgery antitumor protocols, novel therapeutic strategies 
are highly needed for GBM, some of which may already 
Figure 4. (A) Effects of treatment of T98G cells with 4 µM R8-PNA-a155 and R8-PNA-a221 on production of caspase-3 mRNA, analyzed by reverse transcrip-
tion-quantitative polymerase reaction. RPL13 mRNA was used as internal control and data are presented relative to untreated cells. (B) Effects of treatment 
of T98G cells with 2 µM and 4 µM R8-PNA-a155 and R8-PNA-a221, as indicated, on production of caspase-3, analyzed by Bio-Plex assay. (C and D) Effects 
of 4 µM R8-PNA-a155 and R8-PNA-a221 on caspase-3/7 activity analyzed by the Muse caspase-3/7 Assay kit. Results are presented as the average ± standard 
deviation from three independent experiments. (D) Representative plots from the caspase-3/7 activity experiments. *P<0.05 and **P<0.01 with comparisons 
indicated by brackets.
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be tested in therapeutic protocols for other tumors (44-47). 
MicroRNAs are putative molecular targets, based on current 
knowledge: glioma-associated oncomiRNAs have been 
described whose expression is deeply impaired during onset 
and progression of these tumors (48-50); the expression 
of some oncomiRNAs is significantly associated with 
Figure 5. (A-D) Apoptosis was measured following single administration of increasing amounts of R8-PNA-a155 (A, B and D) and R8-PNA-a221 (A, C and D) 
in T98G cells. (E-H) Effects of single administration of R8-PNA-a155 and R8-PNA-a221 on TMZ-treated T98G cells. Panels E-G show representative plots 
from cells treated for 48 h as indicated and analyzed for Annexin V release. (H) Quantification of the results obtained from T98G cells treated with 4 µM 
antagomiR PNAs in the presence of TMZ. T98G cells were treated with 400 µM TMZ in the absence or in the presence of the indicated concentrations of 
R8-PNA-a155 and R8-PNA-a221. Results are presented as the average ± standard deviation from three independent experiments. TMZ, temozolomide; PNAs, 
peptide nucleic acids. *P<0.05 and **P<0.01 with comparisons indicated by brackets.
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outcome, therefore rendering them a very useful potential 
marker in the analysis of non-invasive liquid biopsies (51); 
miRNA therapeutics have been recently demonstrated to be 
useful in the treatment of a variety of human pathologies, 
including gliomas (52-55); miRNA pathways might exhibit 
a patient-to-patient variability, allowing the design of 
personalized protocols (56,57); and miRNA targeting might 
be employed to overcome drug-resistance, an issue of great 
relevance in the management of patients with glioma (58-61).
Gliomas express two microRNAs, miR-155-5p and 
miR-221-3p, at high levels, and these are associated with 
oncogenic activity and strong antiapoptotic effects (62-64). 
These effects are mediated by a putative targeting by these 
miRNAs of the 3'UTR sequence of the proapoptotic caspase-3 
mRNA, possibly leading to a downregulation of caspase-3 
expression (42,43,65). Therefore, miR-155-5p and miR-221-3p 
appear to be appealing targets for the development of 
therapeutic protocols for gliomas.
The use of PNAs is very promising since, from their 
introduction following the first description by Nielsen et al (18), 
they have been considered for therapeutic interventions on a 
variety of human pathologies, including cancer. However, 
several issues should be considered in proposing PNAs as 
therapeutic tools in miRNA therapeutics: their delivery to 
target cells; possible off-target effects due to the fact that 
a single miRNA might recognize several mRNA targets; 
and the presence in the 3'UTR of each target mRNA of 
several potential miRNA binding sites, which might require 
co-administration of different anti-miRNA molecules, leading 
to further complications of the off-targeting issue.
The major conclusion of the present study is that two 
miRNAs (miR-155-5p and miR-221-3p), highly expressed 
in gliomas and demonstrated to regulate caspase-3 gene 
expression (42,43,65), were the target of PNA-based induction 
of apoptosis in the TMZ-resistant T98G glioma cell line. Of 
note, TMZ was able to further increase apoptosis induced 
by the PNAs targeting these two miRNAs. Furthermore, 
combined treatment using low PNA doses and TMZ resulted 
in higher pro-apoptotic effects, suggesting a sensitization of 
glioma cells to TMZ.
The present results support the concept that anti-miRNA 
strategy could lead to therapeutic relevant inhibition of 
biological functions of miRNA-regulated mRNAs (8-11) and 
that PNA-based anti-miRNA molecules are very promising 
reagents as a tool for the development of therapeutic 
protocols for tumor cell growth inhibition. In this context, 
and considering the low uptake of PNAs (21), further research 
on PNA analogues is necessary with the aim of increasing 
delivery, improving stability, controlling the intracellular 
distribution and the in vivo tissue targeting. In addition, 
PNAs selectively interacting with specific mature miRNAs, 
pre-miRNAs or pri-miRNAs might be compared as a further 
step for the selection of the best candidate PNA-based drugs. 
The present study strongly indicated that the combined 
treatment of target glioma cells with PNAs inhibiting both 
miR-155-5p and miR-221-3p was associated with a significant 
improvement of the efficacy of the treatment, as evidenced 
by their effects on cell apoptosis. This conclusion supports 
the strategy of designing multifunctional PNA-containing 
systems or nanocarriers (67,68), enabling to perform targeting 
of multiple miRNA sequences. Finally, our data are compatible 
with a sensitization of T98G cells to TMZ, supporting 
previous observations indicating anti-miRNA strategy may 
be a potential tool to reverse drug resistance, which is one of 
the major unresolved issues in the therapeutic management of 
patients with glioma (58-60).
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